MediciNova Future Growth

Future criteria checks 0/6

MediciNova's earnings are forecast to decline at 6.1% per annum. EPS is expected to decline by 4.8% per annum.

Key information

-6.1%

Earnings growth rate

-4.8%

EPS growth rate

Biotechs earnings growth13.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated25 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

TSE:4875 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-12N/AN/A1
12/31/2025N/A-12N/AN/A1
12/31/2024N/A-11N/AN/A1
9/30/2024N/A-10-9-9N/A
6/30/20241-8-9-9N/A
3/31/20241-8-8-8N/A
12/31/20231-9-7-7N/A
9/30/20231-10-11-11N/A
6/30/2023N/A-12-12-12N/A
3/31/2023N/A-14-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-13-13-13N/A
6/30/20220-13-13-13N/A
3/31/20220-13-9-9N/A
12/31/20214-10-9-9N/A
9/30/20214-11-8-8N/A
6/30/20214-11-9-9N/A
3/31/20214-11-12-12N/A
12/31/2020N/A-14-11-11N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-12-9-9N/A
3/31/2020N/A-11-9-9N/A
12/31/2019N/A-13-9-9N/A
9/30/2019N/A-11-8-8N/A
6/30/2019N/A-16-8-8N/A
3/31/2019N/A-15-8-8N/A
12/31/2018N/A-15-9-9N/A
9/30/2018N/A-16-9-9N/A
6/30/2018N/A-13N/A-9N/A
3/31/2018N/A-13N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-7N/A
6/30/2017N/A-10N/A-7N/A
3/31/2017N/A-11N/A-7N/A
12/31/2016N/A-11N/A-7N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-7N/A
9/30/2015N/A-8N/A-7N/A
6/30/2015N/A-9N/A-7N/A
3/31/2015N/A-9N/A-7N/A
12/31/2014N/A-9N/A1N/A
9/30/20146-3N/A-2N/A
6/30/20146-3N/A-2N/A
3/31/20146-4N/A-3N/A
12/31/20136-4N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4875 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4875 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4875 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4875's revenue is forecast to grow faster than the JP market.

High Growth Revenue: 4875 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 4875's Return on Equity is forecast to be high in 3 years time


Discover growth companies